Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.

Standard

Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis. / Smith, Miriam J; Esparza, Sonia; Merker, Vanessa L; Muzikansky, Alona; Bredella, Miriam A; Harris, Gordon J; Kassarjian, Ara; Cai, Wenli; Walker, James A; Mautner, Viktor Felix; Plotkin, Scott R.

In: CLIN BIOCHEM, Vol. 46, No. 7-8, 7-8, 2013, p. 698-700.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Smith, MJ, Esparza, S, Merker, VL, Muzikansky, A, Bredella, MA, Harris, GJ, Kassarjian, A, Cai, W, Walker, JA, Mautner, VF & Plotkin, SR 2013, 'Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.', CLIN BIOCHEM, vol. 46, no. 7-8, 7-8, pp. 698-700. <http://www.ncbi.nlm.nih.gov/pubmed/23261835?dopt=Citation>

APA

Smith, M. J., Esparza, S., Merker, V. L., Muzikansky, A., Bredella, M. A., Harris, G. J., Kassarjian, A., Cai, W., Walker, J. A., Mautner, V. F., & Plotkin, S. R. (2013). Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis. CLIN BIOCHEM, 46(7-8), 698-700. [7-8]. http://www.ncbi.nlm.nih.gov/pubmed/23261835?dopt=Citation

Vancouver

Smith MJ, Esparza S, Merker VL, Muzikansky A, Bredella MA, Harris GJ et al. Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis. CLIN BIOCHEM. 2013;46(7-8):698-700. 7-8.

Bibtex

@article{9d6e6e7fcf1b4108a0576ab12d0492f0,
title = "Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.",
abstract = "Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in patients with these disorders. We explored whether S100? would act as a biomarker of tumor burden in NF since S100? is a classic immunohistochemical marker of astrocytes, oligodendrocytes and Schwann cells and a small study showed S100? concentrations correlate with the volume of vestibular schwannomas.",
author = "Smith, {Miriam J} and Sonia Esparza and Merker, {Vanessa L} and Alona Muzikansky and Bredella, {Miriam A} and Harris, {Gordon J} and Ara Kassarjian and Wenli Cai and Walker, {James A} and Mautner, {Viktor Felix} and Plotkin, {Scott R}",
year = "2013",
language = "English",
volume = "46",
pages = "698--700",
journal = "CLIN BIOCHEM",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "7-8",

}

RIS

TY - JOUR

T1 - Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.

AU - Smith, Miriam J

AU - Esparza, Sonia

AU - Merker, Vanessa L

AU - Muzikansky, Alona

AU - Bredella, Miriam A

AU - Harris, Gordon J

AU - Kassarjian, Ara

AU - Cai, Wenli

AU - Walker, James A

AU - Mautner, Viktor Felix

AU - Plotkin, Scott R

PY - 2013

Y1 - 2013

N2 - Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in patients with these disorders. We explored whether S100? would act as a biomarker of tumor burden in NF since S100? is a classic immunohistochemical marker of astrocytes, oligodendrocytes and Schwann cells and a small study showed S100? concentrations correlate with the volume of vestibular schwannomas.

AB - Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in patients with these disorders. We explored whether S100? would act as a biomarker of tumor burden in NF since S100? is a classic immunohistochemical marker of astrocytes, oligodendrocytes and Schwann cells and a small study showed S100? concentrations correlate with the volume of vestibular schwannomas.

M3 - SCORING: Journal article

VL - 46

SP - 698

EP - 700

JO - CLIN BIOCHEM

JF - CLIN BIOCHEM

SN - 0009-9120

IS - 7-8

M1 - 7-8

ER -